Big Health UK partners with Evergreen PR to boost adoption of Sleepio.
- Sleepio, an evidence-based treatment, is recommended by NICE.
- Insomnia affects one in three people weekly in the UK.
- Limited access to CBTi has been a longstanding issue.
- Evergreen PR aims to make Sleepio widely available in England.
Big Health UK has teamed up with strategic healthcare PR agency, Evergreen PR, to enhance the adoption of Sleepio, a leading digital solution for insomnia. Sleepio stands out as an evidence-based digital treatment offering cognitive behavioral therapy for insomnia (CBTi). The National Institute for Health and Care Excellence (NICE) recommends it as the primary treatment for this common sleep disorder.
Insomnia is a significant health issue in the UK, affecting approximately one in three people every week. This condition not only disrupts sleep but also has far-reaching effects on mental and physical health, diminishing the quality of life and functionality. Despite the clear need, access to CBTi has been severely limited due to a shortage of trained therapists.
In May 2022, Sleepio achieved a historic milestone by becoming the first digital treatment endorsed by NICE as both clinically effective and cost-saving for the NHS. However, despite its proven success in Scotland, where it has been readily available nationwide since 2021, Sleepio has not yet gained widespread availability in England.
Evergreen PR is set to spearhead a strategic communications initiative aimed at introducing Sleepio across England. According to NICE, this initiative will not only save the NHS money but will also improve patient access to the recommended treatment. Moreover, it will help reduce the current dependency on secondary treatments like sleeping pills, which often come with adverse side effects such as dependence and withdrawal.
Will Goddard, managing director for Big Health UK, emphasized the importance of this partnership, stating, “We’re excited to be working with Evergreen as a key strategic partner to support our mission to help millions back to good mental health.” He stressed that while Sleepio’s recommendation by NICE marked a significant achievement, its true value lies in its accessibility to patients in need.
Leigh Greenwood, the founder and managing director of Evergreen PR, expressed enthusiasm about ensuring that digital treatments like Sleepio reach more people. Her agency aims to make health happen by facilitating access to effective, guideline-based treatments through impactful campaigns. Earlier this year, Evergreen successfully campaigned for The Sleep Charity, which led to government backing for a National Sleep Strategy.
The collaboration between Big Health UK and Evergreen PR seeks to expand Sleepio’s reach, offering new hope for millions affected by insomnia in England.
